Skip to main content

Table 1 Patients' characteristics

From: Effects of pegylated G-CSF on immune cell number and function in patients with gynecological malignancies

Patient

Tumor (histotype)

FIGO Stage

Tumor grade

Number of previous chemotherapy cycles

UPN #1

Endometrial carcinoma (endometrioid)

Ic

G3

4

UPN #2

Endometrial carcinoma (serous)

IV

G3

5

UPN #3

Ovarian carcinoma (serous)

IIIb

G3

4

UPN #4

Cervical carcinoma (squamous)

Ib2

G2

2

UPN #5

Ovarian carcinoma (serous)

IIIc

G3

3

UPN #6

Endometrial carcinoma (mixed)

Ic

G2

1

UPN #7

Ovarian carcinoma (serous)

Ic

G3

4

UPN #8

Ovarian carcinoma

IIIc

G3

4

UPN #9

Ovarian carcinoma (serous)

IIIc

G3

4

UPN #10

Endometrial carcinoma (endometrioid)

Ic

G3

4

UPN #11

Ovarian carcinoma (endometrioid)

IIIc

G3

3

UPN #12

Ovarian carcinoma (endometrioid)

IIIb

G2

4

  1. The demographic characteristics of the 12 patients enrolled in this study are shown. Patients had not received any chemotherapy in the 21 days preceding the commencement of the carboplatin/paclitaxel regimen (see Materials and Methods for further details). FIGO = International Federation of Gynecology and Obstetrics. UPN = Unique Patient Number.